LncRNA BCAR4 expression predicts the clinical response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
LncRNA BCAR4 expression predicts the clinical response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
复制标题
LncRNA BCAR4表达预测局部晚期乳腺癌患者新辅助化疗的临床反应
DOI：
10.3233/cbm-210048
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Luo Q
中科院分区：
文献类型：
--
作者：
Gan FJ;Li Y;Xu MX;Zhou T;Wu S;Hu K;Li Y;Sun SH;Luo Q
背景：新辅助化疗（NAC）是局部晚期乳腺癌（LABC）的重要治疗手段。然而，没有有效的生物标志物来预测疗效。因此，迫切需要新的生物标志物来预测LABC对NAC的反应。LncRNA BCAR 4已在多种恶性肿瘤组织中检测到，并被用作诊断和预后的新生物标志物。然而，LncRNA BCAR 4预测LABC对NAC的反应尚不清楚。目的：探讨LncRNA BCAR 4在3种不同评价体系中对NAC治疗LABC疗效的预测作用。方法：首先，利用TCGA数据库分析LncRNA BCAR 4在33种恶性肿瘤中的表达，进一步探讨其在乳腺癌中的表达及其对乳腺癌生存和预后的影响。进一步采用定量方法检测48例LABC患者癌组织中LncRNA BCAR 4的表达水平，分析LncRNA BCAR 4与临床病理状态、3、RECIST 1.1、Miller-Payne（MP）评分及是否达到pCR评价系统下NAC疗效的相关性。结果：TCGA数据分析发现LncRNA在多种恶性肿瘤组织中高表达，包括乳腺癌。而相对低表达者，高表达患者的总生存时间较短。LncRNA BCAR 4的高表达与肿瘤大小有关，I期与其他分期之间表达存在差异，但与淋巴结阳性和激素受体状态无明显相关性。三个评价体系中，仅RECIST 1.1评价体系中LncRNA BCAR 4对LABC的NAC有预测作用。LncRNA BCAR 4的表达与临床分期、Ki-67%和激素受体状态无明显相关性，与局部晚期乳腺癌患者在新辅助化疗期间是否获得pCR无明显相关性。结论：LncRNA BCAR 4在LABC组织中高表达，可作为预测NAC治疗LABC疗效的有效指标。
BACKGROUND: Neoadjuvant chemotherapy (NAC) is an important treatment for locally advanced breast cancer (LABC). However, there are no effective biomarkers to predict the efficacy. Therefore, there is an urgent need for new biomarkers to predict the response of LABC to NAC. LncRNA BCAR4 has been detected in a variety of malignant tumor tissues and used as a new biomarker for diagnosis and prognosis. However, LncRNA BCAR4 predicts the response of LABC to NAC is unclear. OBJECTIVE: Explore the predictive effect of LncRNA BCAR4 on the efficacy of NAC for LABC in three different evaluation systems. METHODS: First, the TCGA database was used to analyze the expression of LncRNA BCAR4 in 33 kinds of malignant tumors, and further explore its expression in breast cancer and its impact on the survival and prognosis of breast cancer. Furthermore, quantitative methods were used to measure the expression level of LncRNA BCAR4 in cancer tissues of 48 LABC patients, and the correlation between LncRNA BCAR4 and clinicopathological status and response to NAC under the evaluation system of 3, RECIST1.1, Miller-Payne (MP) score and whether it reaches pCR,was analyzed. RESULTS: TCGA data analysis found that LncRNA is highly expressed in a variety of malignant tumor tissues, including breast cancer. And relatively low expression, the shorter the overall survival time of high expression patients. The high expression of LncRNA BCAR4 is related to the size of the tumor, and there are differences in expression between stage I and other stages, but there is no obvious correlation with the positive lymph node and hormone receptor status. Among the three evaluation systems, only in the RECIST 1.1 evaluation system LncRNA BCAR4 has a predictive effect on NAC for LABC. The expression of LncRNA BCAR4 has no significant correlation with clinical stage, Ki-67% and hormone receptor status, and has no significant correlation with whether patients with locally advanced breast cancer obtain pCR during neoadjuvant chemotherapy. CONCLUSION: LncRNA BCAR4 is highly expressed in LABC tissues and may be an effective marker for predicting the efficacy of NAC for LABC.